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Abstract 
 
Obesity is a growing concern worldwide and is associated with increased risk of prostate cancer 
(PCa) and poor patient prognosis. Metformin (MET) is reported to be protective against PCa in 
type 2 diabetics as they are at a reduced risk of developing PCa and have a better prognosis if 
they do in fact develop PCa. My thesis examined the effects of MET on two prostate cancer cell 
lines, LNCaP and PC3 cells. MET caused alterations in morphology and cell detachment in both 
cell lines. MET counteracted the effects of leptin which was independent of AMPK activation.  
PC3 cells incubation with conditioned media and treated with MET caused increased AMPK 
activation and decreased AKT activation. MET was found to act independently of AMPK 
although it caused an increase in AMPK activation in PC3 cells. It appears that MET represents a 
promising adjuvant therapy for obese PCa patients. 
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1.0 Introduction:
 
Obesity is a growing global concern.  There are several measures of obesity such as body 
mass index (BMI), waist to hip ratio (WHR) and body fat percentage with the most commonly 
used criteria due to its ease of measurement and calculation being BMI (weight in kilograms 
divided by the square of the height in metres squared (kg/m2)). A person is classified as 
overweight if their BMI is 25 to 29.9, and obese if they have a BMI of 30 or greater as defined 
by the World Health Organization (WHO).  
 Obesity is most prevalent in western countries such as the United States, where it is 
reported that 35.7% of people above the age of 20 are obese, with women having a slightly 
higher rate than men at 36.3% compared to 35.5%1. Canada is slightly better off than United 
States in terms of obesity, where nearly a quarter (23%)2 of all adults are obese. However, 
obesity is not only seen in North America. Obesity is a major concern in countries like Australia 
where more than 60% of adults are obese3. Although obesity in China is only a third of the 
prevalence of that found in Australia, it has increased by over 400% in the past 20 years in China 
compared with only a 20% increase in Australia over the same period3. Obesity has increased at 
a staggering rate in areas where obesity was previously not normally seen. 
 In 2008 it was reported that 1.46 billion adults worldwide were determined to be 
overweight, with 502 million classified as obese4.  The effects of this obesity pandemic are far 
reaching as it burdens societies with premature mortality, morbidity associated with many 
chronic disorders and negative effects on health-related quality of life5. This places a financial 
strain on the system in multiple ways; whether it is paying for the direct cost of medical 
treatment associate with obesity and the myriad of comorbidities associated with it, or by having 
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to pay disability for people who are too obese to work or the amount of lost productivity that can 
be attributed to obesity. In in 1997 it was estimated that the direct cost of obesity in Canada was 
over $1.8 billion, corresponding to 2.4% of the total health care expenditures6, with an additional 
$2.7 billion in estimated indirect costs. An updated study found that the direct cost attributed to 
being overweight and obesity was $6.0 billion, which is 4.1% of total healthcare expenditure, 
with $3.9 billion attributed solely to obesity7. Also the total indirect cost associated with obesity 
and its comorbidities to be a staggering $52.6 billion for just 20067. Canada is not isolated in this 
trend of increasing cost of obesity. A systemic review found that obesity accounted for 0.7-2.8% 
of the total health-care costs and that obese individuals had medical costs 30% higher than those 
with normal weight8. The increased prevalence of obesity is estimated to account for 27% of 
growth in US healthcare expenditure from 1987 to 20019, and it is projected to account for 16-
18% of total US healthcare expenditure by 203010. 
 Aside from the medical cost, society faces the burden of indirect costs of obesity by 
employees missing work (absenteeism) or reduced productivity. In Sweden, obese individuals 
were 1.5-1.9 times more likely to take sick leave than were individuals with a healthy weight11.  
In the US alone the loss of productivity due to obesity is estimated to be as high as $390-580 
billion in loss to the economy12.   
 The etiological causes for the obesity pandemic are still being investigated. However, it is 
believed that two factors play a major role which are 1) a global shift towards a “Western diet”, 
high in simple carbohydrates, energy-dense and saturated fats (animal fats), and 2) a rapid 
decrease in the demand of physical activity in daily life according to the WHO. Regardless of the 
cause of obesity it is associated with numerous severe health risks including hypertension, 
coronary artery disease, and Type 2 diabetes mellitus13. Obesity has also been shown to be 
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associated with the incidence of several cancers such as colon, rectal, breast, ovarian, cervical, as 
well as prostate cancer and leukaemia14.  
 
1.1 Adipokines and Adipocytes: 
 Adipose tissue can be classified as brown adipose tissue (BAT), or white adipose tissue 
(WAT). WAT is primarily comprised of adipocytes, preadipocytes, macrophages, endothelial 
cells, fibroblasts and leukocytes. Brown adipocytes are largely responsible for generating heat in 
neonates, which comprise ~5% of the total adipose mass15. Accordingly, BAT is abundantly 
filled with mitochondria, which produce heat as a normal by-product of ATP production. 
Throughout the progression into adulthood, the number of brown adipocytes diminishes as 
thermoregulation is maintained through other mechanisms, such as shivering. White adipocytes 
were previously thought of as merely a storage warehouse for excess energy, being stored as 
triglycerides and released and used in times of energy shortage (fewer calories consumed than 
needed). For example if energy intake exceeds energy expenditure by just 5% every day, it can 
result in an increase in 5 Kg of fat over 1 year16, and if this trend continues for many years it can 
lead to becoming overweight or obese. However, in 1994 the idea for WAT being strictly a 
passive storage system was discarded for it being a highly dynamic organ with the discovery of 
Leptin (LEP)17. Today over 50 adipokines18 (proteins produced & secreted by adipose tissue) 
have been discovered, that can act locally in an autocrine/paracrine fashion or systemically as an 
endocrine hormone (Figure 1)19. They can exert their biological actions on target cells by 
classical ligand-receptor endocrine mechanisms.  Two of these adipokines, LEP and adiponectin 
(ADIPO), have received much of the attention. 
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Figure 1 — Basic schematic of adipokines and their paracrine and endocrine environments.  
Adipokines can travel to their target organs via the circulatory system and/or migrate to surrounding tissue to 
induce their various endocrine and paracrine effects.  
 
 
1.2 Leptin: 
 LEP plays an important role in homeostatic regulation and in hunger/satiety. LEP is 
predominantly produced by WAT and is a 167 amino-acid protein with a molecular weight of 16 
kDa20. The protein belongs to a family of cytokines with four long helices in their structure.  LEP 
is encoded by the ob (LEP) gene on chromosome 7 in humans21. LEP carries its function through 
specific receptors, and there are 6 isoforms of this receptor that differ in their intra-cellular C-
terminal sequences22. One is a long isoform LepRb, while the others have shorter C-terminal 
sequences22, 23. Although there are several isoforms, only the LepRb full-length isoform contains 
the distinct transmembrane subunits necessary to induce the intracellular signalling cascade from 
external cues24. Studies on mice have found that this LepRb full-length isoform is most 
important for transmitting the LEP signal to the cells and is located predominantly in the 
hypothalamus and not in most other tissues25, while other isoforms are found throughout the 
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body26. LEP functions by binding to the receptor to cause receptor dimerization leading to the 
activation of the janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway27. 
 LEP acts through its receptor to inhibit eating rather than to initiate the feeling of fullness 
known as satiety. In rodents LEP production is stimulated and remains elevated for several hours 
after feeding, and it was also found that administration of leptin greatly reduced food intake28. 
However, this does not seem to be the case in humans as acute changes in food intake are not 
accompanied by short-term increases in plasma leptin levels16, but LEP is still involved in the 
regulation of adipose tissue and body weight. When LEP binds to its receptors it exerts its effects 
on two populations of hypothalamic neuropeptides. On one population, LEP reduces the 
expression of orexigenic (feeding inducing) peptides, while on the other it increases the 
expression of anorexigenic genes (loss of appetite)16. Thus, LEP has an effect on controlling 
body weight through these two antagonistic pathways.  
 The circulating LEP concentration is proportional to total adipose tissue mass (Figure 
2)29,30, meaning that the more obese an individual is the higher the amount of circulating LEP is. 
Conversely, decreased serum levels of LEP are circulating in lean individuals. Serum LEP levels 
also appear to be 3 times higher in women compared to men31.  The problem with obesity in 
rodents as well as humans is that LEP keeps on increasing as obesity increases but it no longer 
has the same weight control effects as the person or rodent become LEP resistant. Rodents with 
dietary-induced obesity (DIO) are hyperleptinemic, but become resistant to effects of exogenous 
LEP administration. However they do respond to LEP administration via the 
intracerebroventicular route, indicating that a defect in the blood-brain barrier plays a role in 
LEP resistance for animals32,33.  When DIO rodents were given LEP directly into the CNS, it was 
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marked by weight loss and reduced food intake also33. Obese humans like DIO rodents also 
demonstrate LEP resistance but not only are they resistant to endogenous LEP but also to 
exogenous LEP administration34. However, LEP has not yet been injected directly into the CNS 
of human subjects. This LEP resistance that is brought on by obesity can be potentially explained 
by the limitations of the blood-brain-barrier LEP transport system. The transport of LEP into the 
cerebrospinal fluid (CSF) is mediated by a short form of the LEP receptor35, which is 
saturable32,36. This receptor is not as efficient in obese individuals as it is in lean individuals. The 
transporter is saturated at a plasma LEP concentration of about 25 ng/ml32,36, above which there 
is no further increase in CSF LEP concentration despite the high value of plasma LEP 
concentration. Since the excess LEP from obese individuals isn’t able to enter the CSF and is 
thus unable to trigger the hypothalamus to trigger an increased response, which could account for 
LEP resistance.  
 LEP does not exert all of its effects through the hypothalamic cells, but through other 
tissues that have the LEP long form receptor; such as skeletal muscle, liver, adipose tissue as 
Figure 2 — Relationship of LEP and ADIPO serum levels with adiposity.  
LEP production is proportional to adiposity while ADIPO production is inversely proportional to 
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well and pancreatic β cells16. The product of LEP binding to the receptor in tissue such as muscle 
is the stimulation of lipid oxidation, which would promote insulin sensitivity37,38.   
 
1.3 Adiponectin:  
A year after LEP was discovered ADIPO was discovered in murine adipocytes39, and in 
1996 it was discovered in human adipocytes40.  The major functions of ADIPO are anti-
atherogenic, anti-inflammatory and insulin-sensitizing effects41. ADIPO is a 244 amino acid 
protein with a molecular weight of 30 kDa that is almost exclusively produced in WAT. 
However, there are sources that suggest that BAT also produced some ADIPO42. ADIPO has 
also been found to be produced by cardiomyocytes in humans and mice43. The gene coding for 
ADIPO is located on chromosome 3 in humans. ADIPO exists largely as low molecular weight 
(LMW) trimers, medium molecular weight (MMW) hexamers and high molecular weight 
(HMW) nonamers44. Full length ADIPO can also be cleaved to produce globular ADIPO 
(gADIPO). ADIPO is a protein hormone, and exerts multiple biological effects throughout the 
body mediated by the specific receptors AdipoR1, AdipoR2, and T-cadherin45. AdipoR1 is 
expressed ubiquitously but at highest levels in striated muscles while AdipoR2 is most highly 
expressed in the liver. Both AdipoR1 and AdipoR2, like G-protein coupled receptors contain 
seven transmembrane domains46, except that they have C-terminal domain on the extracellular 
side and the N-terminal domain intracellular, which is the opposite of G-protein coupled 
receptors47. T-cadherin has been shown to possibly play a very minor role in ADIPO signaling, 
whereas AdipoR1 and AdipoR2 mediate the vast majority of responses to ADIPO46. AdipoR1 
and AdipoR2 mediate their responses in different manner. AdipoR1 works via activation of 
AMP-activated protein kinase (AMPK) while AdipoR2 works through activation of peroxisome 
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proliferator-activated receptor (PPARα) (Figure 3)46, 47. Full length ADIPO acts on both skeletal 
muscle and the liver by stimulating the phosphorylation and subsequent activation of AMPK, 
while gADIPO is only capable of doing this in skeletal muscle48.  When AMPK activation is 
blocked the fatty-acid combustion along with glucose utilization is inhibited, suggesting that 
ADIPO works through and AMPK dependent manner48. ADIPO is one of the most abundant 
adipokines and circulates in the body at 0.05% of total serum proteins39. Like LEP, ADIPO also 
has higher serum concentration in women49.  
Figure 3 — AdipoR1 and AdipoR2 signaling pathway.  
AdipoR1 and AdipoR2 appear to be integral membrane proteins; the N-terminus is internal and the C-terminus is 
external; opposite to the topology of all reported G protein–coupled receptors (GPCRs). AdipoR1 is abundantly 
expressed in liver, skeletal muscle, macrophages, hypothalamus and so on, while AdipoR2 is expressed in liver, 
white adipose tissue (WAT), vasculature and so on. AdipoR1 and AdipoR2 serve as receptors for adiponectin and 
mediate increased AMP-activated kinase (AMPK) and PPARs activities, thereby regulating glucose and lipid 
metabolism. Both Ca2þ/CaMKKb and AMP/LKB1 are necessary for adiponectin-induced full AMPK activation. 
Adapted from Yamauchi, T. 201454. 
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 Recently, it has been realised that HMW ADIPO is the active form50, 51, and an increase 
in HWM compared to total ADIPO is associated with improvements in insulin sensitivity, as 
shown in individuals taking thiazolidinedione for the treatment of type 2 diabetes50.  Increased 
levels of total ADIPO have also been shown to increase insulin sensitivity while decreased 
ADIPO levels are associated with insulin resistance52.  In a study with mice that were fed a high 
fat diet, ADIPO levels were observed to drop, and when ADIPO was administered it resulted in 
significant improvement in insulin resistance that was seen as a result of high fat feeding53, 54. 
Thus, ADIPO is described as an insulin-sensitizing adipokine. It has also been shown that a 
small increase in circulating ADIPO levels causes a transient decrease in basal blood glucose 
levels. This is believed to be the result of ADIPO sensitizing the body to insulin. In addition, 
ADIPOR causes an increase in fatty-acid oxidation in muscle, decreases plasma glucose and 
leads to overall weight loss55-57.  
The expression of ADIPO receptors is negatively regulated by insulin through the 
activation of phosphoinositide-3-kinase (PI3K) and inactivation of FoxO158. So an inverse 
correlation exists between plasma insulin levels and ADIPO receptor expression59. Although 
ADIPO is produced predominately by adipocytes it has an inverse relationship with total 
adiposity, opposite to LEP adiposity relationship (Figure 2). As an individual becomes more 
obese they have lower levels of circulating ADIPO and as person becomes leaner they have 
higher circulating levels of ADIPO52. Thus obesity negatively acts on ADIPO in two ways. 
Firstly there is a decrease in ADIPO levels associated with obesity and secondly through reduced 
expression of ADIPO receptors, which in turn leads to reduced ADIPO sensitivity and increased 
insulin resistance, thus perpetuating the cycle. Also, it has been found that low levels of 
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circulating plasma ADIPO or hypoadiponectinemia is in itself a marker for insulin resistance  
and significantly related to type 2 diabetes (T2D) development60-62.  
ADIPO has also been shown to have anti-inflamitroy and anti-atherogenic properties as it 
is seen to accumulate in damaged vascular walls and beneficially modulate the endothelial 
inflammatory response to vascular injury63. 
  Adipokines such as LEP and ADIPO have several differing actions on cell proliferation 
and cell cycle regulation. 
 
2.0 The Cell Cycle: 
 The cell cycle refers to the overall process in which a cell grows, replicates its DNA and 
then divides into two identical daughter cells, each with an exact copy of the original DNA. The 
mammalian cell cycle is very intricate and tightly regulated, with several checkpoints and 
redundancies. The cell cycle can be divided into two major phases, interphase and mitosis64. 
Interphase has 3 sub stages that include two growth phases (G1, G2), with G1 preceding S phase 
and G2 succeeding it. In G1, the cell begins to grow and increases protein production in 
preparation for DNA replication, which occurs in S phase. This is followed by the second growth 
phase, G2. After passing through the different phases of interphase a cell is ready to divide by 
mitosis in which two equal daughter cells well be produced. Between every phase of the cell 
cycle there are critical check points that are called Restriction Points (RP) or commonly referred 
to as the ‘point of no return’64. These RPs, allow a cell to perform a self-assessment to determine 
if the previous stage was sufficient to exclude potential termination of replication or cell death. 
This entire process is unidirectional, and as such once a cell reaches a RP it either passes 
“assessment” and continues or if it fails it is programmed to stop dividing and possibly undergo 
programmed cell death. One of the most vital transitions is from G1 to S, as this is where the cell 
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commits to replicating its DNA. Cells that are not dividing are termed quiescent (non-
proliferating) and enter G0 or a resting state of the cell cycle64.   
Even this simplified representation of the cell cycle reveals the extreme complexity in 
which the cell cycle is regulated (Figure 4). If any mutations or errors occur in a cell they will be 
passed on to future daughter cells if not corrected before DNA replication or division. To ensure 
that the cell transitions seamlessly from the stages and beyond the RPs, several proteins are used 
as regulators of the cell cycle providing either stimulatory or inhibitory effects.    
 
Figure 4 — The stages of the cell cycle.  
The site of activity of regulatory CDK/cyclin complexes is also indicated64. 
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 Of these proteins the major cell regulators are the cyclin-dependent kinases (CDKs), that 
requires the binding of a specific cyclin to become active65,66.  Once activated the CDK/cyclin 
complex regulates many downstream signaling pathways in cell cycle progression (Figure 4). 
Cylin E and CDK2 form a complex that is responsible for cell cycle progression from G1 to S 
phase67. CDK inhibitors counteract the stimulatory effects of the CDK/cyclin complexes68, by 
either 1) preventing CDK/cyclin complex from forming, or 2) by binding to the formed complex 
and inactivating it, thus preventing the complex from affecting the downstream targets. 
Depending on their function this group of cell cycle inhibitors can be divided into two distinct 
families, the INK4 (p15, p16, p18, p19) family and the Cip/Kip family (p21, p27, p57)68,69.  
 As shown in figure 1, the predominate G1 cyclin/cdk complexes are cyclin D/cdk4/6 and 
cyclin E/cdk2. Following the activation of these complexes there is a subsequent activation of 
the cyclin A/cdk2 in S phase and cyclin A/cdk1 and cyclin B/cdk1 in G2 and M phases70. 
Although cyclin D is expressed periodically unlike the other cyclins it is synthesized as long as 
the growth factor stimulation continues71.  
 In terms of cell cycle regulation, the sole target phosphorylated by cyclin D/cdk4/6 is the 
retinoblastoma tumor suppressor (Rb). During early G1, Rb becomes phosphorylated and 
inactivated by cyclin D/cdk4/6 complexes, subsequently releasing the transcription factor E2F-1. 
This positively regulates the transcription of genes whose products are required for the 
progression into S phase such as cyclin E and cdc2572. Once a cell reaches full activation of 
cyclin E/cdk2 in late G1, the cell has passed the restriction point. Following this, the cell is 
committed to enter the cell next phase of the cell cycle and can’t return back to G1 until a full 
cell cycle is completed. Importantly, limiting the amount of active cyclin E/CDK2 available 
keeps cells inactive until a mitogenic signal intervenes. Cyclin E expression is dependent on its 
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regulation by E2F transcription factors once they have been released from Rb. When a cell is in 
the G0 quiescent state, Rb is in a hypophosphorylated state and bound to E2F64 inhibiting 
transcription of cyclin E mRNA.  
Initially, these mitogenic signals induce the expression of cyclin D and cdk 4/6 which 
then forms an active kinase state with p27 in order to phosphorylate Rb. This phosphorylation 
causes the dissociation of E2F from Rb which then transcribes cyclin E allowing for the 
formation of the active kinase cyclin E/cdk264. This newly formed cyclin E/cdk2 then works 
through a positive feedback loop to cause Rb to become hyperphosphorylated thus causing E2F 
to fully activate its target genes and induce the transition into S phase and DNA replication. 
As previously mentioned p27 is a key regulator of the G1-S phase transition. It serves to 
prevent premature activation of cyclin E/cdk2 in early G1 and also helps with the assembly and 
activation of cyclin D/cdk4/6 in late G173. Therefore p27 can be thought as a positive regulator 
of G1 progression by this assembly and nuclear import of cyclin D/cdk4/673. It is now believed 
that the balance between the levels of cyclin D1 and p27 is the main regulating mechanism for 
controlling proliferation of cells instead of their absolute levels within the cells74. 
 The discovery of p27 was first shown by its inhibition of cyclin E/cdk2 and cyclin 
A/cdk2 in cells arrested by TGF-β and contact inhibition75-78. Specifically, p27 was shown to 
exhibit its inhibitory effect on cyclin E/cdk2 by binding to the catalytic cleft of the complex, 
preventing it from phosphorylating Rb79. Mitogenic growth factor signals have been shown to 
cause a loss of p27 levels and activity. In contrast p27 has been shown to increase in response to 
differentiation signals80-82. 
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The mRNA expression of p27 does not change through the cell cycle but instead the 
protein content of p27 is regulated by stabilizing phosphorylation in G0/early G1 and inactivating 
phosphorylation in late G1/early S phase80, 83. 
 Phosphorylation of p27 can result in loss of its inhibitory activity or degradation, 
however not all phosphorylation sites on p27 cause ubiquitin mediated degradation and/or 
nuclear export, as some facilitate p27 effects on cell cycle arrest and protect it from these 
events84. One of the important phosphorylation events occurs on the threonine 187 residue 
(T187) by the “newly-activated‟ cyclin E/CDK2 holoenzyme85. Phosphorylation at this 
particular site targets p27 to the Skp2 multi-protein ring finger ubiquitin (Ub) nuclear 
degradation complex and accounts for nearly 80% of total p27 protein degradation86. While 
evidently a predominant mode of p27 inactivation, protein quantification of Skp2 revealed that 
p27 levels decline rapidly in mid G1, prior to the rise of Skp2 expression seen in late G187, 88. 
This observation suggested the presence of a novel proteolytic pathway involved in p27 
degradation. Subsequent research has since verified the presence of such a mechanism albeit 
within a different sub-cellular location. Phosphorylation of the serine 10 residue (S10; likely by 
hKIS or AKT) serves to translocate p27 out of the nucleus and into the cytoplasm87. Here, it can 
be recognized by KPC1 and KPC2, members of the KIP1-ubiquitilaytion promoting complex 
that target p27 for early G1 Ub-mediated degradation88.   
Another phosphorylation event occurs in the cytoplasm on the threonine-157 residue 
(T157) of newly translated p27 protein by AKT87. Once phosphorylated, the family of 14-3-3 
proteins interacts with p27T157 and sequesters it within the cytoplasm where it can no longer 
inhibit cyclin E/cdk2, which will allow for the transcription of S-phase dependent genes89. 
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A significant stabilizing phosphorylation to p27 is caused by AMP-activated protein 
kinase (AMPK) on threonine 198 (T198)90,91. This stabilizing phosphorylation is important in 
quiescence and early G1 as this T198 phosphorylation keeps p27 levels high and facilitates 
inhibition of cyclin E/cdk2 leading to cell cycle arrest. Liang et al. (2007) discovered that in 
breast cancer cells, activated AMPK (pAMPK) directly phosphorylated p27 on T198 (p27T198)90. 
This then causes cell cycle arrest by increasing the stability of the protein. Also interesting to 
note is that Rattan et al. (2005) demonstrated that AICAR; an AMP analog which can indirectly 
up-regulate AMPK through its upstream kinase, liver kinase B1 (LKB1), increases pAMPK, 
stabilizes p27 and p53. AICAR also inhibited the AKT pathway through its upstream activator 
PI3K. Phosphorylation on T198 increases total p27 protein half-life when compared to T198 
mutated p27 cells when activated with AICAR90. Thus, this stabilizing phosphorylation on p27 is 
extremely important to cell cycle arrest and required for optimal cell cycle progression and may 
play a role in cancer development/progression.  
When there are fundamental alterations in cell cycle regulation this leads to uncontrolled 
cell proliferation. The loss of cell cycle regulation is mainly due to mutations in the cell that 
affect either proto-oncogenes, or tumor suppressor genes64. This rapid and uncontrolled cell 
proliferation that has the potential for metastasis is classified as cancer.  
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3.0 Prostate Cancer: 
 The prostate is an exocrine organ in males that is part of the reproductive system. The 
main function of the prostate is to produce and expel an alkaline fluid comprising 20-30% of 
semen volume that neutralizes the acidity of the vaginal tract. Prostate cancer (PCa) is screened 
for in the general population by using one of two methods. The first being the digital rectal 
examination (DRE) in which a physician inserts a gloved lubricated finger into the rectum of the 
patient and exams the prostate through the rectum, for irregular shape, size and texture. The 
second being prostate specific antigen (PSA) testing, in which the serum PSA levels are 
measured to determine if the levels are beyond the normal range. There is some controversy in 
the field regarding the use of PSA to screen for PCa. Some men with PCa might not have 
elevated levels of PSA which is false negative; which occours 10% of the time, and at other 
times some men might have elevated PSA levels without having or ever developing PCa, known 
as a false positive, which is a common occourrence. Only 1 in 4 abnormal PSA levels is due to 
PCa92. Another disadvantage of PSA screening is that it can detect PCa that may not pose a 
serious health risk to the individual, yet due to the detection of elevated PSA levels the man will 
undergo a biopsy and potentially treatment, even though the cancer would not have affected the 
individuals life. Recent research has shown that 50% of cancers that are detected by the PSA test 
may never need to be treated. The majority of these men go on to have treatment, which is 
unnecessary in most cases92. PSA screening is not recommended on a population wide bases, but 
mainly recommended to individuals at high risk for PCa and should be discussed with their 
doctor to determine if PSA screening is right for them92.  This makes the efficacy of PSA 
screening in reducing overall mortality from PCa a source of great controversy93,94, which stems 
from over diagnosis and lack of specificity of PSA in discriminating between PCa and benign 
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prostatic hyperplasia94. While PSA has been shown to correlate very well with tumor volumes95, 
it is unable to predict with certainty the biological aggressiveness of the disease or its prognosis. 
Thus there is still a need to develop a non-invasive test using biomarkers to identify clinically 
relevant PCa. 
Once diagnosed with PCa there are several ways to manage PCa, among the most 
common are androgen deprivation therapy (ADT), radical prostatectomy, external beam 
radiation therapy or chemotherapy or a combination of these methods. Androgen receptor 
positive PCa can be initially managed through ADT, which is the chemical equivalence of 
physical castration. ADT can be accomplished through several methods, such Orchiectomy 
(surgical castration), where the testicles are surgically removed or through chemical castration 
using luteinizing hormone-releasing hormone (LHRH) analogs, which reduces the testosterone 
produced in the testicles. Another option for ADT is using anti-androgens, which bind to the 
androgen receptors prevents the androgens from having the desired effect on PCa. All of these 
treatment options reduce the overall levels of androgens available to enhance PCa growth and 
metastasis. ADT is used as a first line of treatment for metastatic PCa96. The cancer initially 
responds to ADT and regresses but after time the cancerous cells can become androgen-
independent (also known as castration-resistant or hormone-refractory PCa) and are no longer 
responsive to ADT, making the tumour more aggressive97. As a result of these treatments some 
men might become impotent and depressed along with other side effects due to ADT, and this 
poses yet another question regarding the efficacy of PSA screening. 
PCa will account for 24% of newly diagnosed cancers in the United States, and will 
account for 10% of cancer related deaths in men92. According to the Canadian Cancer Society, 
one in 8 men will develop PCa during his lifetime (the risk is highest after age 60) and one in 28 
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will die of it. Also in Canada PCa was the most common diagnosed cancer excluding 
melanomas98.  Despite much research on PCa, its cause still remains unclear. However several 
risk factors have been identified such as age, race/ethnicity, nationality, family history, genetics 
and diet99, 100.  Obesity has also been shown to be a risk factor for PCa101. A recent study has 
shown visceral fat accumulation; quantified by computerized tomography (CT) is a specific risk 
factor for PCa102. However obesity has a greater association with PCa mortality as well as higher 
grade and more aggressive tumours103.   
 A geographic correlation exists between areas of high PCa and obesity incidence. Not 
surprisingly PCa incidence is highest in North America and Western Europe. Specifically 
England and Wales, are associated with the highest obesity rates, whereas Asian countries have 
the lowest incidence104,105. Recently there has been a rapid rise in PCa incidence in Asian 
countries105 that is mirrored by the explosive obesity trend in Asian regions such as China. The 
search for the molecular link between obesity and PCa as well as many other cancers has led to 
the focus on adipokines as cancer growth regulatory factors, particularly LEP and ADIPO. 
 A positive correlation between circulating LEP levels and the risk of large-volume 
prostatic tumours has been found106. There is also evidence that serum leptin levels are correlated 
with measures of prostate cancer risk including PSA and Gleason score in patients with PCa107. 
Gleason score is the most common grading method for PCa, starting at 1 and going to 5. A score 
below 3 is rarely used for PCa because the tissue looks and acts like normal cells, while higher 
scores reflect a worse prognosis and metastisis92. In vitro studies support the proliferating effect 
of LEP on androgen independent PCa cell lines108, which mimic castration-resistant PCa. High 
LEP concentration is predictive of high grade disease and more advanced tumors109. Since 
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obesity is associated with increased PCa incidence, as well as more aggressive tumours, it is 
suggestive that LEP is a potential mediator of this because it follows the same trend.  
 ADIPO has been found to be negatively correlated with adiposity. Lower ADIPO levels 
were found in patients with PCa as opposed to healthy controls and patients with benign prostatic 
hyperplasia 110. In that same study it was also found that ADIPO was negatively correlated with 
tumour grade and Gleason scores such that lower ADIPO levels were associated with higher 
grade tumours and higher Gleason score. Since obesity is associated with increased LEP levels 
and decreased ADIPO levels, obesity correlates negatively with PCa prognosis. 
 
 
 20 
4.0 Metformin:  
 Metformin (MET) is an oral medication for T2D that is used to reduce blood glucose 
levels in obese or overweight people with normal kidney function111. It was initially developed in 
the 1920s as a by-product of the synthesis of N,N-dimethylguanidine112, but interest in MET died 
down and was later rediscovered and used for the treatment of diabetes. MET is the most widely 
used oral anti-diabetic medication for T2D, due to its clinical effectiveness and low toxicity 
profile 112.  In 2010, 48 million prescriptions of MET and its generic formulations were filled in 
the United States.  
 Obesity is a well-recognized risk factor for T2D that is also a risk factor for cancer 
itself113, 114. Certain types of cancers are more common in individuals with diabetes, and diabetes 
is also associated with reduced survival after development of cancer115. PCa is one of the cancers 
that men with T2D appear to be at a higher risk for, with a health risk of 1.19 compared to those 
men without T2D116.  However, some studies provide contradicting evidence in which T2D is 
reported as being protective of PCa117. Some researchers suggest that the protective effect is due 
to the reduced testosterone production in diabetics118,119, while other attribute it to the medication 
that the individuals are on for management of T2D 120. Nonetheless with PCa the chances of 
dying from the disease are increased with T2D121. 
 It has been found that patients with T2D on MET have a lower risk of developing cancer 
and lower mortality from cancer as opposed to patients on other glucose lowering therapies122-126. 
In preclinical studies that utilized MET in vivo it was found to decrease PCa cell line survival by 
up to 50%, while reducing normal prostate epithelial cells by only 20%, which suggests that 
MET selectively targets the rapidly dividing PCa cells while leaving the healthy cells relatively 
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undisturbed127. Several different pathways have been suggested to account for the anti-cancerous 
effects of MET which include the inhibition of mammalian target of rapamycin (mTOR) 128, and 
by the activation of the AMPK in some cancers129, 130 while also being able to exert its anti-
cancerous effects in an AMPK independent pathway in some cell lines127, 131129, 130. MET seems 
to be a double edged sword in the fight against T2D and cancer simultaneously and thus a 
promising drug for therapy.  
As mentioned earlier PCa is initially responsive to androgens, but later on becomes 
hormone refractory or androgen independent. To mimic these conditions in vivo 3 different cell 
lines are often utilized. LNCaP cell which are androgen receptor positive represent hormone 
responsive PCa, and PC3 and DUI45 are androgen receptor negative and mimic hormone 
refractory PCa. In vivo studies using LEP found it caused an increase in the phosphorylation of 
AKT at Threonine 473 in LNCaP, PC3 and DUI45 cell lines, but only very weakly in the latter 
2132. LEP also caused a significant increase in the number of PC3 and DUI45 cells, but only a 
mild increase in the number of cells for LNCaPs133. ADIPO on the other hand has been shown to 
have a dose dependant growth inhibitory effect on PC3 cells in vivo, likely due to an increased 
phosphorylation of AMPK at Threonine 172 (T172)134. AMPK phosphorylation at T172 has also 
been observed in LNCaP cells in response to ADIPO treatments in vivo135, and surprisingly 
ADIPO caused increased phosphorylation of AKT at two sites Threonine 308 and Serine 473. 
The results of that study suggest that ADIPO stimulates both AMPK and PI3K/AKT pathways 
with the later having a dominant effect on the activation mTOR in LNCaP cells.  Activation of 
AMPK has also been observed in PC3 cells when treated with MET in vivo134.  
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5.0 Hypothesis:
 
 Based on the background literature we a priori hypothesized that:  
1. MET will act as inhibitor of the cell cycle through the activation of AMPK in androgen 
receptor positive LNCaP cells as well as androgen receptor negative PC3 cells.  
2. AMPK inhibition with Compound C will abolish the effects of MET.  
3. Met will counteract the effects of LEP on cell cycle progression.  
4. Adipose tissue from cancer and non-cancer patients will elicit cell cycle effects on 
androgen receptor positive LNCaP as well as androgen receptor negative PC3 cells.  
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6.0 Materials and methods:
 
6.1 Cell Lines and Cell culture. Human prostate cancer cells, LNCaP and PC3, which are 
androgen receptor positive and androgen receptor negative respectively, were obtained from the 
American Tissue type Culture Collection (ATCC, Manassas, VA). LNCaP and PC3 cells were 
maintained in RPMI 1640 (Wisent, St.Bruno, QC), 10% Fetal Bovine Serum (FBS, Hyclone, 
Thermo Fisher Scientific, Whitby, ON), 3% & 1% Antimitcotic/Antibiotic (Wisent) respectively, 
at 37°C and 5% CO2.  
6.2 Metformin and cell growth. LNCaP and PC3 cells were plated into 6 well plates in RPMI 
1640 for 48 hours until approximately 70-80% confluence. At 48 hours the media was 
replenished and the cells were treated with various concentrations (1-100 nM) of 1,1-
dimethylbiguanide hydrochloride (metformin, Santa Cruz Biotechnology. Santa Cruz, CA) for 
24 hours, in the presence and absence of the AMPK inhibitor Compound C (CC)(10 µM, 
Millipore). 
6.3 Cell harvesting and lyzing. The 6 well plates were aspirated and washed twice with cold 
Phosphate Buffered Saline (PBS, Wisent) scraped and transferred into a single centrifuge tube 
with 1 mL of cold PBS. Samples were then centrifuged at 2,300 g at 4oC for 5 minutes. The 
supernatant was discarded and the pellet was then re-suspended in TENT++ (0.2% Tent [TRIS, 
EDTA, NaCl, and 0.2% Triton x-100]), Sigma protease inhibitor cocktail and Sigma phosphatase 
inhibitor cocktail 2, (Sigma, Oakville, ON). Samples were then sonicated for 5 seconds at 10% 
power (Microsonic Unltrasonic Cell Disruptor, VWR, USA) and centrifuged for 10 minutes at 
15,700 g. The supernatant was then removed and stored at -84°C for future analyses. 
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6.4 Human Samples. In collaboration with The Princess Margaret Hospital and the University 
Health Network, male patients who were undergoing prostatectomy or invasive exploratory 
surgery were recruited to the study. After patient consent was received and prior to the surgery 
the patient’s serum was collected and their weight, age, and medication were identified. The 
study is run in a blind manner as to not bias any of the results. During the surgery adipose tissue 
samples were obtained from the patients. Two samples were obtained, one from peri-prostatic fat 
for patients undergoing prostatectomy as well as visceral fat from the abdomen. For patients 
undergoing exploratory surgery or nephrectomy the samples obtained were from the visceral fat 
storage from the abdomen as well as the second sample from the peri-prostatic/renal fat 
depending on the surgery.  
6.5 Conditioned Media. To generate the conditioned media (CM) human fat from 35 patients 
was incubated with RPMI (15 ml od RPMI/ g of minced tissue), that contained 10% FBS and 1% 
Antimitcotic/Antibiotic. The samples were placed in RPMI media for 30 minutes and incubated 
37°C with 5% CO2. The media was aspirated out and the fat samples removed and coarsely 
minced with scissors and placed in the appropriate amount of RMPI media for 1 hour and 
incubated at 37°C with 5% CO2. Subsequently the RPMI media was aspirated and replenished 
and left for 24 hrs incubated 37°C with 5% CO2 with periodic mixing. After 24 hous a sample of 
the fat was frozen and stored at -84oC for future analysis, and the CM collected and stored at -
84oC. 
6.6 Conditioned Media Treatment. PC3 cells were seeded in 6 well plates with RPMI until cells 
were 70-80% confluent. The media was aspirated and washed with PBS and then CM from either 
ACM or PCM was added and left for 24 hours. Additional plates were treated with 25 nM 
metformin and or 10 µM Compound C, depending on whether sufficient volume of CM was 
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obtained as described above. Cells grown in normal RPMI containing only 10% FBS were used 
as controls. All treatments were for 24 hours. Prior to collection of the cells the CM was 
collected and frozen at -84oC for future analyses and the cells were harvested as described above.  
6.7 Western Blotting. Protein concentrations were determined using a Bradford Assay (BioRad) 
and 25 µg of protein was loaded onto 12% SDS polyacrylamide denaturing gels (PAGE), were 
separated by electrophoresis and transferred onto a PVDF membrane (Bio Rad, Mississauga, 
ON) at 4°C overnight. Blots were stained with amido black to determine protein transfer 
efficiency. Membranes were blocked for 2 hours in 10% low fat milk and then washed with 
TBST (Tris-Buffered Saline with 0.5% Tween 20, TBST) for 4X10 min. Subsequently 
membranes were incubated with the appropriate specific primary antibodies (Abs) in 5% BSA at 
4°C overnight. Following the primary incubation the membranes were washed with TBST for 
4X10 min and then incubated with specific secondary Abs (in 5% low fat milk) for 1 hour and 
subsequently washed again in washed with TBST for 4X10 min. Proteins of interest were then 
visualized by ECL Chemiluminescent HRP Substrate (Millipore) using the Kodak In vivo FX 
Pro Imager to detect the chemiluminescent signal which was quantified using Carestream 
imaging software (version 5.0.5.31).    
Proteins of interest were studied by Western blotting with primary Abs for mouse monoclonal 
anti-p27Kip1 (1:3000, BD Biosciences), rabbit polyclonal anti-p27T198KIP1 (1:2000, R&D Systems, 
Minneapolis, MN), rabbit polyclonal anti-pAKTT308 (1:500, Cell Signalling), rabbit polyclonal 
anti-AKT total  (1:3000, Cell Signalling), rabbit polyclonal anti-pAMPKT172 (1:1000, Cell 
Signalling), rabbit polyclonal anti-AMPK total (1:2000, Cell Signalling), goat polyclonal anti-
ADIPOR1 (1:2000, Santa Cruz Biotech), mouse monoclonal anti-Cyclin E (1:1000, AbCam 
Cambridge, MA), rabit polyclonal anti-COX IV (1:5000, Abcam) and mouse monoclonal anti-β-
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actin (1:50000, Abcam) for 24 hrs at 4°C. Secondary Abs (1:5000, rabbit, mouse or goat, 
Promega, Madison, WI) or β-actin (1:20000, anti-mouse, Promega), were incubated with the 
membrane at room temperature in 5% low fat milk for 1 hr. All protein levels have been 
corrected to β-actin, to account for any errors due to uneven loading. 
6.8 Statistical analyses. GraphPad’s Prism 5 for windows version 5.02 was used for all statistical 
analysis. For MET concentration alone a 1-way ANOVA was utilized along with Tukey’s post 
hoc test to compare the different concentrations. MET and Compound C treatments were alayzed 
using a two-way ANOVA was utilized in combination with bonferroni post hoc test. For MET, 
Compound C and LEP treatments, as well as CM treatments multiple t-tests were used to 
evaluate the desired comparisons. Differences were considered significant for all tests when p < 
0.05.  
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7.0 Results:
 
7.1 LNCaP – Metformin Treatment 
LNCap cells treated with 50 and 100 nM detached from the plate and demonstrated 
distinct morphological changes. pAMPKT172 was increased by approximately 200% with 1nM 
MET treatment with a steady decline evident as MET concentration increased reaching  42 ± 
16% of control at 50 nM, an 80% reduction from 1 nM MET (Figure 5 A,B). pAKTT308 
displayed a dramatic decrease  with MET treatment, declining to levels that were 11 ± 7% of 
those in non-treated control cells (Figure 5 A,C). pAKTT308 was always lower than pAMPKT172 
values at all concentrations of MET, as predicted. This suggests that AMPK activation may lead 
to AKT suppression. Predictably p27T198 displayed a similar pattern as pAMPKT172, reaching its 
lowest levels at 50 nM (Figure 5 A,D).  p27 protein levels were also decreased by MET, 
reaching the lowest value at 38 ± 14% of non-treated control cells at a concentration of 100 nM 
(Figure 5 A,E). COX IV protein trended towards being decreased by MET (p=0.07) (Figure 5 
A,G). Cyclin E protein levels were decreased by MET treatment, reaching levels that were 30 ± 
8% of those seen in untreated control cells at 100 nM (Figure 5 A,F). AdipoR1 was also 
decreased by increasing concentrations of MET, reaching levels that were 40% lower than in 
control cells at 100 nM MET (Figure 5 A,H).  
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Figure 5 — LNCaP cells treated with Metformin.  
(A) Representational blots for LNCaP cells for treated with MET, (B-H) graphical representation of relative optical 
density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Letters which differ 
represent a significant difference (p<0.05). n= 6-12/group 
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7.2 LNCaP – Metformin and Compound C Treatment 
In order to determine the role of AMPK in mediating the effects of MET, experiments 
were conducted in the presence of the AMPK inhibitor Compound C (CC). LNCaP cells were 
treated with 0, 10, 25 and 50 nM of MET alone and in combination with 10 µM CC.  Inhibition 
of AMPK by 10 µM CC had no effect on previously observed MET effects on all proteins 
(Figure 6 B-H). Interactions were observed for pAKTT308, and COX IV (Figure 6 C,G).  It 
appears that this was a result of an increase in each protein with CC in the absence of MET.  
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Figure 6 — LNCaP cells treated with Metformin and Compound C. 
(A) Representational blots for LNCaP cells for treated with MET and CC, (B-H) graphical representation of relative 
optical density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Graphs have been 
rearranged for clarity. Letters which differ represent a significant difference (p<0.05). n= 6-12/group 
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7.3 LNCaP – Metformin, Leptin and Compound C Treatment 
Since LEP is seen to be elevated in obesity, MET treatments were conducted in the 
presence of LEP to determine if MET can counteract the effects of LEP. pAMPKT172 was 
reduced to approximately 50% of levels found in untreated cells with the addition of MET in the 
presence of LEP. Again no effect of CC was observed. LEP and CC combined caused 
pAMPKT172 to reach its highest levels of 147 ± 13. When MET was added with LEP it caused a 
decrease to 22 ± 4% of untreated control cells. In the presence of CC the same results were 
obtained, with MET causing a decrease to 24 ± 6% (Figure 7 A,B). Since LEP treatments caused 
changes in total AKT (Figure 7 A) we expressed pAKTT308 as a function of total AKT; a similar 
response to pAMPKT172 in which the addition of MET counteracted the effects of LEP and 
caused a decrease in pAKTT308 regardless of the presence of CC (Figure 7 C). MET caused a 
decrease in p27 levels when combined with LEP in the absence of CC, however when MET and 
LEP were combined in the presence of CC the reduction by MET was not observed (Figure 7 
A,E). COX IV trended (p=0.0533) towards being reduced when MET and LEP were combined 
in presence of CC (Figure 7 A,G). p27T198, Cycline E, and AdipoR1 demonstrated no observable 
effects of treatment (Figure 7 D,F,H).  
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Figure 7 — LNCaP cells treated with Metformin, Leptin and Compound C. 
(A) Representational blots for LNCaP cells for treated with MET and CC, (B-H) graphical representation of relative 
optical density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Graphs have been 
rearranged for clarity. * represents significant differences between MET treated cells in the same CC same 
treatment (p<0.05). n= 6-12/group 
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7.4 PC3 – Metformin Treatment 
MET did not affect pAMPKT172 at any concentrations. Since total AMPK concentrations 
appeared to decrease by MET treatment (Figure 8 A), relative pAMPKT172/AMPK was utilized 
for analysis. pAMPKT172/AMPK increased with MET concentrations (Figure 8 B). Total AKT 
levels were also altered by MET treatment (Figure 8 A) and AKT activation was expressed by 
measuring pAKTT308/AKT. pAKTT308/AKT was found to decrease with MET treatment (Figure 
8 C). p27 was reduced by MET where it reached its lowest value of 79 ± 6% of untreated control 
at 25 nM MET. Surprisngly 100 nM MET increased p27 to its highest value of 156 ± 21%of 
control (Figure 8 A,E). p27T198, cyclin E, COX IV and AdipoR1 were found to not be affected 
by MET (Figure 8 D,F-H). 
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Figure 8 — PC3 cells treated with Metformin.  
(A) Representational blots for LNCaP cells for treated with MET, (B-H) graphical representation of relative optical 
density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Letters which differ 
represent a significant difference (p<0.05). n= 6-12/group 
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7.5 PC3 – Metformin and Compound C Treatment 
In order to determine the role of AMPK in mediating the effects of MET, experiments 
were conducted in the presence of the AMPK inhibitor Compound C (CC). PC3 cells were 
treated with 0, 10, 25 and 50 nM of MET alone and in combination with 10 µM CC. CC caused a 
decrease in pAMPKT172 to roughly 50% of the levels in untreated control cells and remained low 
at all concentrations of MET (Figure 9 A,B). pAKTT308 in general was increased by CC 
especially at higher concentrations of 25 and 50 nM MET when combined with CC (Figure 9 
A,C). It was the only protein that showed an interaction between CC and MET.  CC had no 
effect on p27 T198, p27, AdipoR1, COX IV and cyclin E (Figure 9 D-G). COX IV and AMPK 
were undetectable with 10 nM MET and CC treatment (Figure 9 A,G).   
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Figure 9 — PC3 cells treated with Metformin and Compound C. 
(A) Representative blots for LNCaP cells for treated with MET and CC, (B-H) graphical representation of relative 
optical density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Graphs have been 
rearranged for clarity. Letters which differ represent a significant difference (p<0.05). n= 6-12/group 
 37 
7.6 PC3 – Metformin, Leptin and Compound C Treatment 
Since LEP is seen to be elevated in obesity, MET treatments were conducted in the 
presence of LEP to determine if MET can counteract the effects of LEP. CC treatment caused no 
effect on MET effects in LEP treated cells. pAMPKT172, pAKTT308, p27T198, cyclin E, COX IV 
and AdipoR1 showed no significant differences (Figure 10 A-D,F-G). MET reduced p27 in the 
presence of LEP by nearly 2/3rds from 154 ± 31%  to 58 ± 11% of levels observed in untreated 
control cells. In the presence of LEP and CC p27 levels decreased and this was not affected by 
MET treatment (Figure 10 A,E).   
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Figure 10 — PC3 cells treated with Metformin, Leptin and Compound C. 
(A) Representational blots for LNCaP cells for treated with MET and CC, (B-H) graphical representation of relative 
optical density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Graphs have been 
rearranged for clarity. * represents significant differences between MET treated cells in the same CC same 
treatment (p<0.05). n= 6-12/group 
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7.7 PC3 – Conditioned Media Treatments 
In order to determine the paracrine/endocrine effects of adipose tissue on PCa, PC3 cells 
were grown in the presence of CM prepared from human visceral adipose tissue. Addition of 25 
nM MET to the CM caused a doubling of pAMPKT172 protein levels with CM prepared from 
both abdominal adipose tissue (ACM) and periprostatic/perirenal adipose tissue (PCM), which is 
nearly a 60% increase from the effect of MET alone.CC in addition to the CM caused a decrease 
in pAMPKT172 to their lowest point in each depot, with the lowest being 56 ± 5% for ACM. 
Similar to the results seen when MET was combined with CC, there was no effect of CC on 
pAMPKT172 with MET in the presence of CM. The same pattern was present for the ACM and 
PCM. The 2 fold increase with MET treatment and 50% reduction of pAMPKT172 with CC alone 
is more in line with our original hypothesis (Figure 11 A,B). pAKTT308 protein levels in PC3 
cells treated with ACM were decreased with the addition of MET, and a same result was 
observed in cells treated with PCM. When CC was added to PCM the addition of MET caused a 
reduction in pAKTT308 protein levels that did not occour in the cells treated with ACM. The 
pAMPKT172/pAKTT308 antagonism that was hypothesized was more clearly visible in the 
presence of CM (Figure 11 A,C). Where MET caused an increase in pAMPKT172 levels it caused 
a decrease in pAKTT308 levels. CC surprisingly caused a reduction in both pAKTT308 and 
pAMPKT172 but a lesser effect on pAKTT308.  
p27 protein levels in PC3 cells treated with ACM was reduced with the addition of MET, 
which was not observed in cells treated with PCM. In both groups however the combination of 
CM and CC resulted in the highest levels of p27 at roughly 150% of untreated control cells 
(Figure 11 A,E). p27 T198, cyclin E, COX IV and AdipoR1 protein levels were unaltered by the 
CM treatments, similar to MET treatments alone (Figure 11 A,D,F-H).  
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Figure 11 — PC3 cells treated with Metformin and Compound C in the Presence of Conditioned Media. 
(A) Representational blots for LNCaP cells for treated with MET and CC, (B-H) graphical representation of relative 
optical density versus control (Mean ± SEM). Blots standardized to β-actin to correct for loading. Graphs have been 
rearranged for clarity. * represents significant differences between addition of MET treated cells (p<0.05). n= 16-
35/group 
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7.8 PC3 – Conditioned Media Treatments Grouped by Cancer Type 
In the existing results there were low numbers of patients/samples in the NCa and RCa 
group which makes proper statistical analysis difficult. PC3 cells treated with CM from adipose 
tissue, and grouped based on cancer type to see if there exists a difference in the paracrine effects 
of adipose tissue from patients with PCa, renal cancer (RCa) and patients without cancer (NCa).  
pAMPKT172 levels appear to be reduced in ACM for PCa and RCa patients when 
compared to NCa. A similar pattern was seen for total AMPK in ACM treated PC3 cells. For 
treatment with PCM a different pattern emerged, where PCa and RCa were higher than NCa. 
When corrected for the changing total AMPK levels the pAMPKT172/AMPK ratio displayed a 
different pattern. For cells treated with ACM PCa was higher than RCa which was about the 
same as NCa, while for PCM PCa and RCa groups were about the same but lower than the NCa 
group (Figure 12 A). pAKTT308 levels for cells treated with ACM  were higher in the PCa group 
and lower in the RCa group compared to NCa patients. The same pattern was present in cells 
treated with PCM. Total AKT levels were observed to change thus a pAKTT308/AKT ratio was 
utilized. The pAKTT308/AKT ratio for cells treated with ACM was higher in the PCa group  and 
lower in the RCa group compared to NCa patients, however for cells treated with PCM the PCa 
group was at the same level as the NCa group which were both higher than the RCa group 
(Figure 12 B). p27T198 protein levels were unaltered in cells treated with ACM, however PCM 
caused an increase in p27T198 protein levels in PCa when compared to NCa which was similar to 
the RCa (Figure 12 C). p27 protein levels like p27T198 were unaltered with ACM treatment. 
With PCM treatment RCa had a higher value than PCa which in turn had a higher value than 
NCa (Figure 12 D). COX IV was unaltered by ACM, but with PCM PCa and RCa were similar 
and both higher than NCa (Figure 12 F). Cyclin E levels displayed a decreasing possible trend 
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for cells treated with ACM, with NCa being higher than PCa, which was higher than RCa, while 
cells treated with PCM displayed the opposite pattern (Figure 12 E). AdipoR1 protein levels in 
cells treated with ACM was elevated in PCa compared to NCa which was similar to RCa. In cells 
treated with PCM, AdipoR1 levels were highest in NCa group, lower in the PCa group and 
lowest in the RCa group, which might suggest a paracrine effect for AdipoR1, where it decreases 
with cancer from PCM versus ACM (Figure 12 G).  
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Figure 12 — PC3 cells treated conditioned media arranged by cancer type. 
(A-G) graphical representation of relative optical density versus control (Mean ± SEM). Blots standardized to β-
actin to correct for loading. Graphs have been rearranged for clarity. n= 1-31/group 
NCa = non cancer, PCa = prostate cancer, RCa = renal cancer 
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8.0 Discussion: 
 
The ever growing concern with obesity is a justified one. Prevalence of obesity in 
western countries is already high and continues to rise1, 2. It is not only seen in western countries 
but also in other countries around the world including Australia7 and China3, making it a global 
issue. One of the major comorbidities associated with obesity is a risk of developing certain 
types of cancer such as prostate cancer (PCa). Obesity does not only increase the risk of 
developing PCa14, but is also associated with a worse prognosis in obese patients that develop 
PCa compared to healthy individuals of normal weight106. Obesity itself is also a risk factor for 
the development of T2D13, which is also associated with a grimmer prognosis for patients who 
develop PCa115.   However, research has shown that patients taking certain T2D medications (i.e 
metformin) are at a reduced risk of developing, and have a better prognosis if they do develop 
PCa116, 122, 123, 125. Thus, I tried to examine the cellular pathway in which MET acts as a 
protective factor against PCa in two different PCa cell lines.  
Previous studies with breast cancer have shown that MET acts through the activation of 
AMPK resulting in cell cycle arrest130. MET clearly acts in an AMPK independent manner in 
androgen receptor positive LNCaP and androgen receptor negative PC3 cells. It was 
hypothesised that MET would activate AMPK, so experiments were conducted in the presence of 
Compound C (CC), which is an AMPK inhibitor, and thus would alter the results obtained using 
MET alone. In LNCaP cells CC did not affect pAMPKT172, or AMPK total protein levels. 
However in PC3 cells CC was able to inhibit pAMPKT172 at all concentrations of MET to 50% of 
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the levels found in untreated control cells, and there was no concentration of MET that was able 
to overcome the effect of CC. CC did not alter other proteins of interest in both cell lines. The 
fact that other proteins of interest were not affected by CC clearly demonstrates that the 
mechanism of MET effects differentially involves AMPK in LNCaP and PC3 cells. Several 
studies have found that MET acts through an AMPK independent manner to reduce blood 
glucose levels in mice136, as well as in human and rat glioma cells137. However MET has also 
shown to act via an AMPK dependent pathway in MCF7 breast cancer cells, to allow for cell 
cycle arrest effects on cyclin D1, and p27130. Also, MET has been found to have an AMPK 
dependant role on the inhibition of blocking lymphoma cell growth138, suggesting that MET can 
act through an AMPK dependent or independent manner, depending of the type of cells.  
Although LNCaP and PC3 cells were both discovered to be directly AMPK independent 
with regards to MET treatment, that’s where the similarities ended. It is clear that in response to 
MET, LNCaP and PC3 cells behave differently. pAKTT308 protein levels were increased with the 
combined treatment of CC and MET in PC3 cells. LNCaP cells on the other had had no changes 
with combination of MET and CC treatment, yet CC treatment alone increased p27 and 
pAKTT308.  Furthermore there were differences observed with MET treatment such as increasing 
pAMPKT172 in PC3 cells, while pAMPKT172 was decreased by MET in LNCaP cells. MET also 
caused decreases in p27T198, cyclin E in LNCaP cells while p27T198 was unaffected in PC3 and 
cyclin E trended towards increasing. Also p27T198 protein levels displayed a similar pattern to 
that of pAMPKT172 in LNCaP cells treated with MET. No such correlation was observed in PC3 
cells, where pAMPKT172 increased and no changes in p27T198 were observed. Another difference 
was that both cell lines displayed a decrease in p27 protein levels, however at 100 nM MET PC3 
cells increased to its highest value. All these differences clearly indicate that LNCaP and PC3 
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cells respond differently to treatment and this could potentially be due to the difference in 
presence of the androgen receptor, which can alter the intracellular machinery. It has been 
established that that activation of AMPK helps stabilize p27 by phosphorylating it at T198, and 
prevents its degradation90, 91. In LNCaP cells a similar pattern was observed for pAMPKT172 and 
p27T198, yet p27 was not increased but rather appeared to decrease at higher concentrations. 
However this similar trend was not observed in PC3 cells. Instead an increase in pAMPKT172 was 
accompanied by no changes in p27T198 and a decrease in total p27, which would seem to suggest 
that in the more aggressive androgen receptor negative PC3 cells, the link between AMPK and 
p27 is dysfunctional or unimportant. This is in line with research that states that cancer cells that 
have reduced p27 or a lack of p27 regulation are more aggressive than cancer cells with p27 
regulation87, 139. Since p27 was observed to increase at 100 nM of MET and it is known that p27 
is protective with respects to cancer progression, we postulate that cells with low levels of p27 
are susceptible to MET. However, at high concentration of MET the only cells able to withstand 
the toxicity are cells exhibiting high p27 levels, despite the low numbers.   
With MET potentially causing a toxic environment at higher concentrations, we observed 
morphological changes and detachment from the plate in LNCaP cells. We postulate that in the 
less aggressive LNCaP cells treated with MET are undergoing autophagy or apoptosis. A recent 
study has found that there is an increase in pAMPKT172 levels and the ability to cells to enter a 
last ditch effort to survive through autophagy during external environmental stress140. It was 
determined that a certain threshold of AMPK activation is required for the cells to be able to 
utilize this desperate pathway to potentially survive external environmental stresses140. It has 
been shown that activation of AMPK by testosterone through androgen receptor supports 
proliferation and invasion in LNCaP cells141, 142. Our own results are consistent with an interation 
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between testosterone and AMPK in mediating intracellular signaling. This indicates that there is 
a link between testosterone and AMPK activation, and so the presence of the testosterone 
receptor impacts AMPK activation. Even though autophagy is seen as cell death, it can 
detrimental or crucial to cell survival. It has been found that autophagy at earlier stages of cancer 
progression is detrimental as allows the formation of free radicals as well as preventing new 
proteins from being formed and degrading already existing proteins, thus stopping 
progression143. While at later stages autophagy is induced as a protective mechanism to allow 
cancer cells, located in the central areas of the tumor to survive local low nutrient and low 
oxygen microenvironments144, 145.  Initially we expected MET to increase the activation of 
AMPK in a dose dependent manner, which was not the case in LNCaP cells, where the addition 
of MET caused an initial increase followed by a decrease from 1 nM MET. Since MET caused 
an initial increase at 1 nM MET and then followed by a subsequent decrease at higher 
concentrations, it suggests that the environment could have become too “toxic” to allow the cells 
to survive. Since reduced AMPK activation was observed it seems that apoptosis may have been 
induced based on previous reports140, 146. Other studies have shown that in LNCaP cells CC has 
minimal effects of AMPK activation, similar to what was observed in our experiments146. Our 
results would suggest this with the decreased overall protein levels as well as the morphological 
changes and detachment that were observed, that at higher concentrations of MET the cells were 
undergoing apoptosis rather than autophagy. It has also been reported in other papers that 
activation of AMPK is required for cells to enter autophagy to utelize energy from destruction of 
intracellular components (autophagy) topotentially survive the external stresses imposed by the 
environment147, 148. 
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To try to examine the role of MET in a more complete environment, CM was generated 
from two different visceral adipose sites for from PCa patients and subsequently used to treat 
PC3 cells, with MET, CC or a combination of both. The addition of MET to the CM caused an 
increase in AMPK activation from what was observed with MET treatment alone and was 
accompanied by a decrease in AKT activation in both depots. Thus, MET elicited opposite 
effects of AMPK and AKT. When MET was combined with CM it and CC it differed from what 
was observed in our previous experiment without the presence of CM. When PC3 cells were 
treated with MET and CC, CC reduced the levels of pAMPKT172 to roughly 50% and no 
concentration of MET was able to override this inhibitory effect. When treated with CM, MET 
was able to override the inhibitory effects of CC on AMPK activation. MET was found to also 
have an additive effect in the presence of CM as it increased beyond what was seen in MET 
treatments alone. Since the addition of CC to MET in the CM did not cause a change it still 
agrees that MET acts via an AMPK independent manner. Thus MET treatment in CM is more in 
line with our hypothesis that MET activates AMPK which leads to AKT suppression. A possible 
explanation for this is that in the CM that is generated from adipose tissue, there are a plethora of 
other factors some of which are inhibitory while others being activators of cell cycle progression 
and that the responses of PC3 cells to MET in CM experiments may better represent what 
happens in vivo, as opposed to MET alone which appears to be causing an environment that is 
too toxic for the cells. This is consistent with other reports showing MET toxicity being specific 
to PCa cells127.  
Part of the initial study design was to examine if there are differential effects of CM 
generated from abdominal visceral adipose tissue (ACM) and CM generated from 
periprostatic/perirenal adipose tissue (PCM) on PC3 cell cycle regulation. Both depots elicited 
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similar results with a few exceptions suggesting that both visceral adipose depots contribute 
similarly to cancer growth. This suggests endocrine effects on growth microenvironment might 
dominate over paracrine effects. However, there were differential effects on the activation of 
AKT between the two different depots. pAKTT308 had a 25% higher activation with PCM 
treatment versus ACM treatment. Also MET caused a greater decrease in pAKTT308 protein 
levels in ACM. As with AMPK, CC had no effect on pAKTT308 proteins levels with ACM 
treatment, but did cause a reduction with PCM treatment when combined with MET and CC. 
This suggests that there may be other adipose derived factors which affect which ones are 
expressed differentially by the 2 adipose depots.  
As can be seen from this study, MET seems to be a promising area of research for PCa 
prevention and treatment. Overall MET seemed incredibly toxic to the cells on its own especially 
the LNCaP cells, and less so on the more aggressive PC3 cells. MET also lowers blood glucose 
levels in patients thus potentially lowering the amount of directly available fuel for cancer cells. 
It is uncertain if MET alters the metabolic environment of cancer cell, so that needs to be 
investigated but MET has direct effects on PCa cells that are AMPK independent, and has 
potential future in management and treatment of PCa in association with obesity.  
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9.0 Limitations and future directions: 
 
As with any experiment or set of experiments there are always a certain set of limitations 
and improvements that can be made. One of our major limitations is that all experiments were 
done in cell cultures not in a whole body environment or in vivo. As we see from our 
experiments, treatment with MET alone produced different results than when MET was added to 
CM generated from patient adipose tissue. This approaches mimicking the tumor environment 
but it does not replicate it. For future studies these cells will need to be implanted into animals 
and try either injecting or ingesting MET to see if the metabolism of MET alters its action and to 
see how that action occurs in vivo. 
With the results obtained we postulated that at higher concentrations of MET that the 
cells were undergoing some form of cell death, so markers of cell death would need to be utilized 
in the future to determine if MET is killing PCa cells, specifically the LNCaP cells. To determine 
if apoptosis is occurring markers such TUNEL assay and caspase cleavage could be utilized.To 
determine if autophagy is occurring Beclin I and LC3 II will need to be analyzed.   
For our experiments, LNCaP and PC3 cells were used and tested. This allowed for 
comparisons between androgen receptor positive and androgen receptor negative cell lines. If the 
same experiments were to be conducted with DU145 cells which are also androgen receptor 
negative PCa cells, it will allow for a greater generalization between androgen receptor negative 
cells, in which we would expect similar results to the PC3 cells.  
A limitation of this study is that number of patient samples that were obtained for use in 
CM treatment. The vast majority of cases were patients with PCa, and only a few that had NCa 
or RCa. This makes it more difficult to do analysis based on cancer type, but more patients of the 
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latter two groups are being obtained an analysed by our lab, to allow for a better comparison in 
the future. Also with regards to the patients, a lot of the patients were within the overweight 
group with a BMI of 25 to 29. More patients with BMI less than 25 and greater than 30 need to 
be recruited to the study to be able to observe is BMI has any effect on the cells prepared from 
their adipose tissue.  
We are unsure if MET has the potential to alter the microenvironment or the properties of 
adipose tissue in patients who are on it for management of type II diabetes. A study can be 
designed with the same conditions as above to exam if patients on MET have a different 
adipokine profile compared to patients not on MET and to examine if this difference translates to 
different growth environments for PCa. 
In order to conduct all the required experiments roughly 3 grams of adipose tissue is 
required from each depot. A drawback of the CM experiments was that we were limited by the 
amount of adipose tissue that was collected during surgery. We were limited by the amount of 
tissue obtained as sometimes only 0.2 grams of adipose tissue were obtained. Further guidelines 
and protocols need established with The Princess Margret Hospital of the amount of fat required 
for the experiments to try to obtain the required amount of adipose tissue to allow for all 
experiments. Also The Princess Margret Hospital might be limited in the amount of adipose 
tissue that they are able to be extract safely from each patient as some patients are learner than 
others.  
To determine if MET as well as CM are arresting the cell cycle, FACS analysis needs to 
be conducted which is planned and will be done in our lab shortly.  
 52 
Since all MET experiments in cell culture were conducted using LNCaP and PC3 cells 
for comparison, the LNCaPs should also be used for CM experiments, and it is currently being 
conducted in our lab. Alongside the LNCaP use for CM, experiments using the patients’ serum, 
are being conducted in PC3 and LNCaP to determine if the patients serum has similar effects to 
those observed from CM generated from adipose tissue.  
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